Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
January 04 2018 - 4:37PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP)
(“Aurinia” or the “Company”) today announced that in
order to replace its prior expired base shelf prospectus and
corresponding shelf registration statement it has filed a
preliminary short form base shelf prospectus (the “Preliminary
Shelf Prospectus”) with the securities commissions in each of
the provinces of Ontario, Alberta and British Columbia in Canada,
and a corresponding shelf registration statement on Form F-10 with
the U.S. Securities and Exchange Commission (the “SEC”)
under the U.S./Canada Multijurisdictional Disclosure System.
The Preliminary Shelf Prospectus and corresponding shelf
registration statement, when made final or effective, will allow
Aurinia to offer up to US$250,000,000 of common shares, warrants,
subscription receipts, debt securities or any combination thereof
during the 25-month period that the Preliminary Shelf Prospectus is
effective. The Company has no immediate intention to undertake an
offering. However, the Preliminary Shelf Prospectus will enable
Aurinia to potentially access new capital if and when needed. The
amount and timing of any future offerings will be based on the
Company’s financial requirements and market conditions at the time.
In addition, the Preliminary Shelf Prospectus and corresponding
shelf registration statement allows Aurinia to meet its contractual
obligation to maintain a valid registration statement to certain
holders of warrants issued under a private placement that took
place in June 2016.
The specific terms of any future offering under the Preliminary
Shelf Prospectus will be established at the time of such offering.
At the time any of the securities covered by the Preliminary Shelf
Prospectus are offered for sale, a prospectus supplement containing
specific information about the terms of such offering will be filed
with applicable Canadian securities regulatory authorities and the
SEC.
The shelf registration statement filed today with the SEC has
not yet become effective. No securities may be sold, nor may offers
to buy be accepted, prior to the time the registration statement
becomes effective. This news release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any jurisdiction in which an offer,
solicitation or sale would be unlawful prior to registration or
qualifications under the securities laws of any such
jurisdiction.
A copy of the Preliminary Shelf Prospectus can be found on SEDAR
at www.sedar.com and a copy of the corresponding shelf registration
statement can be found on EDGAR at www.sec.gov or may be obtained
upon request to Aurinia’s Investor Relations Department using the
contact information set out below.
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The company
is currently developing voclosporin, an investigational drug, for
the treatment of lupus nephritis, focal segmental
glomerulosclerosis, minimal change disease and dry eye syndrome.
The company is headquartered in Victoria, BC and focuses its
development efforts globally.
Forward-Looking Statement DisclaimerCertain of the
statements made in this news release may contain forward-looking
information within the meaning of applicable Canadian securities
law and forward-looking statements within the meaning of applicable
United States securities law. Forward-looking information or
statements may not be based on historical fact, and may include
without limitation statements containing the words “believe”,
“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Forward-looking
statements in this news release include statements regarding the
Preliminary Shelf Prospectus and corresponding shelf registration
statement being cleared by the applicable securities regulatory
authorities and Aurinia’s ability to take advantage of financing
opportunities in favourable market conditions or at all. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties
and other factors are taken into account as part of the Company’s
assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business
conditions in the United States, Canada, Europe, and the other
regions in which Aurinia operates; not receiving the regulatory
approvals, including the further approvals that may be sought from
securities regulatory authorities or the SEC, on the timelines
required or at all, that the prevailing market price of the
Company’s securities may make a prospectus offering in respect of
such securities unattractive to Aurinia as well as those factors
discussed in or referred to under the heading “Risk Factors” in
Aurinia’s Annual Report on Form 40-F for the year ended December
31, 2016 which is available under Aurinia’s profile on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov. Given these risks,
uncertainties and factors, you are cautioned not to place undue
reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180104006404/en/
Aurinia Pharmaceuticals Inc.Investors &
Media:Celia EconomidesVice-President, Public
Affairsceconomides@auriniapharma.comorDennis BourgeaultChief
Financial Officerdbourgeault@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Sep 2023 to Sep 2024